One in four cancer deaths worldwide. That's lung cancer's grim arithmetic – the leading oncological killer globally, relentless in its progression through four distinct stages [1]. Survival statistics reflect the stakes with brutal clarity: five-year rates reach up to 70% at Stage I, then collapse to roughly 10% by Stage IV [2]. The gap between those numbers represents everything – early detection, treatment access, clinical expertise, and time.
Yet the landscape has shifted. Specialized medical teams have rewritten expected outcomes for thousands of patients who've walked through a diagnosis that once felt like a verdict. Innovative treatment combinations have extended survival and preserved quality of life in cases where conventional medicine offered little. Every effective plan starts in the same place – with the individual patient, their specific disease, their circumstances. Nothing less works.
Standard Lung Cancer Treatment Protocols
Cancer type, stage, and overall patient health — these determine which combination makes sense. The basis of lung cancer care includes surgery, chemo-, radiation therapy, and targeted therapy. For advanced disease especially, multimodal approaches – combining several of these – tend to produce the strongest results.
Surgery is the primary treatment for early-stage NSCLC, particularly Stage I and Stage II. Physical removal of the tumor and affected surrounding tissue can achieve high cure rates when the cancer remains localized. Later stages complicate the picture – spread limits surgical impact – though the procedure still plays a role in tumor debulking and symptom relief.
Chemotherapy works systemically – targets rapidly dividing cancer cells throughout the body. Used across all stages but most common in advanced disease (stage III and IV), it typically runs in multiple cycles and frequently is combined with radiation or immunotherapy. Effective – yes. But the side effect burden is real: fatigue, nausea, and immune suppression are common companions [9].
Radiation therapy takes a more localized approach, deploying high-energy rays to destroy cancer cells at specific sites. It works alone or with chemo-, in both NSCLC and SCLC. When surgery isn't an option, radiation can still deliver meaningful disease control and symptom relief. Skin irritation, fatigue, and difficulty swallowing may develop as adverse reactions—depending on the treatment area.
Targeted therapy works differently – blocking the specific genetic mutations and pathways driving tumor growth. Most effective when tumors test positive for EGFR, ALK, or ROS1 mutations, it generally carries a milder side effect profile than chemotherapy and can significantly extend progression-free survival [10]. It is most commonly applied in advanced or recurrent cases.
Conventional treatments form the reliable basis of lung cancer care. But limitations are also well-known: treatment toxicity, tumor resistance, recurrence. The development of alternative medicines and approaches is driven by these shortcomings.
Lung Cancer Therapy: Innovations
Precision is the defining ambition of newer approaches. Greater specificity is achieved in targeting cancer cells. Minimal collateral damage to healthy tissue and meaningful options for patients who haven't responded to conventional therapies are offered.
Dendritic Cell Therapy for Lung Cancer
Dendritic cell therapy – an advanced immunotherapy approach that uses the body's own immune system against cancer. The process: dendritic cells are extracted from the patient's blood, modified to recognize cancer-specific antigens, then reintroduced to trigger a targeted immune response. The result is a treatment that is notably well-tolerated – side effects typically limited to mild flu-like symptoms.
Pioneered by 2011 Nobel Prize winner Ralph Steinman, dendritic cell therapy for lung cancer has demonstrated promising outcomes: prolonged survival and, in select cases, complete remission [3]. Professor Frank Gansauge – an immunotherapy specialist – describes dendritic cells as the "officers" of the immune system, coordinating a precise attack on malignant cells while leaving healthy tissue intact. His clinic integrates this therapy with chemotherapy and radiation to amplify outcomes. The science, the mechanisms, the real-life results – all explored further in a video interview well worth watching.
Prof. Frank Gansauge: How Dendritic Cell Therapy is Transforming Modern Cancer Treatment
Interventional Radiology for Lung Cancer
Conventional surgery isn't always an option. Metastatic disease, compromised health, tumor location – any of these can close that door. Interventional radiology opens another one.
Image-guided and minimally invasive, these procedures reach tumors with precision that conventional approaches can't match – inflicting targeted damage on malignant tissue while surrounding healthy structures remain largely untouched. For patients who've exhausted standard pathways, or simply cannot tolerate them, interventional radiology delivers real disease control without the recovery burden of open surgery.
Thermal ablation weaponizes heat. Two technologies lead the field: high-intensity focused ultrasound (HIFU) concentrates ultrasound energy into a precise tumor site, while laser interstitial thermal therapy (LITT) threads a laser directly to malignant tissue and destroys it from within. What began as a tool for locally aggressive cancers has expanded considerably – thermal ablation now integrates into treatment plans for recurrent and advanced lung cancer, particularly when radiotherapy has run its course without success. The results justify the expansion: recurrence rates drop by up to 50% when ablation forms part of a comprehensive plan [4].
Cryoablation takes the opposite approach – extreme cold rather than heat. Applying freezing temperatures to eradicate malignant cells, it's particularly valuable near critical structures like major blood vessels or bronchi, where preserving collagen and adjacent tissue matters enormously. Studies in advanced NSCLC report impressive progression-free rates: 82%, 97%, and 91% at one, three, and six months respectively [5]. Its safety profile is very encouraging.
Electrochemotherapy (ECT) combines electrical stimulation with direct anticancer drug delivery, enhancing drug penetration into tumor cells. Particularly useful for tumors in strategically difficult positions – near major vessels or in key anatomical zones. Above its cytotoxic effects, ECT is also known to stimulate an immune response and improve local tumor control in more than 70% of cases [6]. As a result, it makes ECT a valuable part of a complementary strategy in advanced lung cancer management, particularly for cases of metastatic secondary lesions or for health-compromised individuals after systemic treatments.
Prof. Kovács on Electrochemotherapy – How Electric Pulses Help Chemo Actually Work
Transarterial Chemoembolization (TACE). Precision over brute force – that's the principle behind TACE. This procedure, minimally invasive, delivers chemotherapy directly through the arteries feeding the tumor. Maximal drug concentration exactly where it's needed and shielding healthy tissue from systemic exposure. And embolization cuts the tumor's blood supply. The result: targeted destruction, with dramatically reduced side effects like nausea and hair loss compared to conventional chemotherapy.
For patients with advanced lung cancer who can't undergo surgery – or whose cancer has developed resistance to standard treatment – TACE has proven particularly valuable. Studies confirm meaningful improvements in both survival rates and quality of life, with recovery times that compare favorably to traditional methods [8].
In a detailed video interview, Professor Attila Kovács explains how TACE works, its dual mechanism of action, and how it can be effectively combined with systemic chemotherapy, radiation therapy, or immunotherapy to enhance outcomes. We invite you to watch this informative interview to learn more about how TACE is transforming the landscape of lung cancer medical treatment.
Prof. Kovács: Why Interventional Oncology Should Be the Fourth Pillar of Cancer Care
Why Choose Innovative Lung Cancer Treatment?
The case is straightforward. Higher survival rates, especially in advanced stages of lung cancer. Fewer side effects. Faster recovery. Targeted mechanisms that spare healthy cells rather than sacrificing them in pursuit of the tumor. These aren't marginal improvements – they represent a fundamentally different philosophy of treatment, one that places quality of life alongside survival as a primary goal.
Demand is responding accordingly. These approaches are being adopted at a pace by lung cancer treatment centers worldwide, and clinics that specialize in them are increasingly being chosen by patients seeking the most advanced care.
Comparative Analysis of Lung Cancer Treatment Methods
Traditional and alternative treatment for lung cancer aren't competing philosophies – they're complementary tools. Understanding the difference matters. Chemotherapy and radiation remain widely used and clinically validated, but their limitations are real: significant side effects, systemic toxicity, and constrained survival rates in advanced disease. Immunotherapy, dendritic cell therapy, and TACE occupy different territory – higher response rates, reduced side effect profiles, and improved survival outcomes, particularly where conventional approaches have reached their ceiling.
The comparison isn't about which approach wins. It is about knowing which tool fits the situation.
| CharacteristicsTherapy type | 2-Year Survival Rate | Response Rate | Duration | Side Effects |
|---|---|---|---|---|
| Standard Treatment | ~25% for advanced cancer | Less than 10% | Several cycles | Severe (nausea, fatigue, hair loss, immunosuppression, skin irritation) |
| Innovative Methods | ~60% for advanced cancer | 45-65% | Up to 4 sessions | Mild (localized discomfort) |
Lung Cancer Success Stories and Patient Testimonials
Data tells one story. Patients tell another – and sometimes more compellingly.
Those who've undergone dendritic cell therapy and TACE report substantial improvements in both survival and daily quality of life. These outcomes emerge from centers that combine advanced technology with genuinely individualized care – and one case illustrates the point clearly.
Anitha Cherian traveled from Canada to Germany after a Stage 4B Non-Small-Cell Lung Cancer diagnosis: distant metastases to the brain, liver, bones, and left adrenal gland, alongside a confirmed EGFR exon 19 deletion mutation. At LDG Laboratories Dr. Gansauge Berg, under Professor Gansauge's guidance, she received care that her home system couldn't offer. Booking Health coordinated the entire journey – translation, transfer, scheduling – they made a logistically daunting process manageable. Her experience demonstrates that, for treatment for advanced lung cancer, specialized international centers represent the best option.
Best Treatment Center for Lung Cancer
Where treatment happens shapes what's possible. Top hospitals for lung cancer don't just treat – they define guidelines, how it's treated globally.
| Hospital | Specialization | Technologies | Recognition |
|---|---|---|---|
| University Hospital RWTH Aachen | Thoracic oncology Minimally invasive surgery | Video-assisted thoracoscopy Radiofrequency ablation | Certificate ISO 9001:2015 IQM Certification Ranked among the top German medical facilities by Focus magazine
|
| Mayo Clinic (USA) | Multidisciplinary approach Precision medicine | Low-dose CT lung screening Robotic surgery Proton therapy | Ranked among the Best Hospitals for cancer by U.S. News & World Report |
| University Hospital Jena | Pulmonology Thoracic surgery | Hybrid interventions Robotic surgery (da Vinci system) | ISO 9001:2015 accredited DIOcert certification Ranked among the top German medical institutions for cardiothoracic surgery by Focus magazine |
| Memorial Sloan Kettering Cancer Center | Comprehensive cancer care Clinical research | Advanced radiation therapy Immunotherapy | NCI-designated cancer center Recognized as one of the top two cancer hospitals in the U.S. for over 30 years |
| ViDia Hospital Karlsruhe | Thoracic oncology Interventional procedures Palliative care | VATS Laser therapy Cryotherapy | The Department of Thoracic Surgery has been certified as a Lung Cancer Center by the German Cancer Society (DKG) since 2011 |
University Hospital RWTH Aachen sits at the intersection of surgical precision and interventional innovation. The Department of Cardiothoracic Surgery handles the full spectrum – from minimally invasive VATS techniques for atypical resections, anatomical lobe removal, and pulmonary metastases, to conventional thoracic surgery when complexity demands it. What distinguishes Aachen isn't any single procedure — it's the infrastructure. The Department of Interventional Radiology runs parallel, extending options beyond the operating theatre with radiofrequency and microwave ablation for tumors that surgery can't optimally reach. Two elite departments, one coordinated strategy.
Mayo Clinic's Lung Cancer Program didn't earn its reputation – it built it, case by case, over decades. One of the largest and most experienced thoracic oncology practices in the United States. Mayo uses a principle: no single specialist should decide alone. Tumor boards gather thoracic surgeons, oncologists, radiologists, and pathologists. The results show up. Mayo pioneered low-dose CT screening before it became standard practice – catching cancers early enough to change outcomes entirely. Their treatment arsenal spans VATS, robotic surgery, proton beam therapy, immunotherapy, and molecularly targeted treatment. When complexity peaks, Mayo is where patients go.
University Hospital Jena has earned its place among Germany's elite lung cancer facilities – not through reputation management, but through published outcomes that Focus magazine consistently ranks at the top. The Department of Cardiothoracic Surgery has built a surgical identity around minimally invasive mastery: VATS and the da Vinci robotic system for robot-assisted thoracoscopic surgery define their approach, particularly for lobectomies requiring extraordinary precision. Laser surgery using Nd:YAG technology extends their reach into cases where conventional instruments fall short – primary tumors, complex metastases, demanding thoracic conditions that other centers redirect elsewhere. Jena doesn't redirect. It operates.
Memorial Sloan Kettering Cancer Center is, by almost any measure, the most experienced dedicated cancer institution on the planet. Over 1,200 lung cancer operations every year – a volume that translates directly into surgical refinement no lower-volume center can replicate. As an NCI-designated comprehensive cancer center, MSK doesn't just meet national survival benchmarks; it exceeds them across every stage, consistently. Their screening program targets high-risk individuals aged 50–80 with low-dose CT – catching disease before it declares itself. Treatment options cover the full landscape: surgery, precisely targeted radiation, advanced chemotherapy, immunotherapy. For patients who want to know they're in the most experienced hands available anywhere, MSK answers that question.
ViDia Hospital Karlsruhe proves that scale isn't the only path to excellence. Certified as a Lung Cancer Center by the German Cancer Society since 2011 – a certification that demands rigorous quality standards, not just application – ViDia's Department of Thoracic Surgery performs more than 80% of procedures through minimally invasive approaches. That figure isn't incidental; it reflects a deliberate commitment to reducing trauma without sacrificing surgical results. Interventional radiology runs alongside surgery; it offers radiofrequency ablation for cases where the scalpel isn't the right tool. Patient-centered isn't a marketing phrase at ViDia – it's the operational model.
Germany's lung cancer centers collectively set the global benchmark. Certification protocols that leave no room for mediocrity, specialist training programs built on decades of concentrated experience, and a treatment philosophy that refuses to separate prognosis from quality of life – this is what genuine excellence looks like in oncological care.
Cost of Lung Cancer Treatment
Stage and treatment type drive costs significantly – but so does location. Germany has established itself as a leading destination for advanced cancer care, combining high clinical standards with transparent, predictable pricing.
Stage 1 typically calls for VATS lobectomy in NSCLC cases. Stage 2 often combines surgery with chemotherapy. Stage 3 demands a more aggressive multimodal strategy – chemotherapy, radiation, and frequently immunotherapy working in combination. Treatment of 4 stage lung cancer in Germany leans heavily on innovative approaches: dendritic cell therapy and TACE feature prominently.
| Treatment Method | GERMANY* | GB | USA |
|---|---|---|---|
| Standard Treatment | €80,000 - €150,000 full course | €90,000 - €165,000 full course | €100,000 - €180,000 full course |
| Innovative Methods | €25,000 - €60,000 full course | €70,000 - €120,000 full course | €100,000 - €150,000 full course |
*Prices may vary depending on the chemotherapeutic agents used, course of treatment, and tumor characteristics.
Against comparable destinations, Germany holds its ground on price without compromising on expertise or technology. Consultation fees, diagnostics, treatment, and post-care costs are presented transparently – patients know what they're committing to before they commit.
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized, innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each case. As a reputable company, Booking Health offers personalized stage 4 lung cancer treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding them to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you on the way of pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for metastatic lung cancer with leading specialists in this field.
Cancer Treatment Abroad: Patient Experiences with Booking Health
Frequently Asked Questions of Our Patients About Lung Cancer Treatment
Send request for treatmentEasy to miss. That's what makes lung cancer so dangerous in its earliest stages – symptoms like persistent cough, chest pain, and shortness of breath blend seamlessly into the noise of everyday illness. Hoarseness, fatigue, unexplained weight loss, and coughing up blood round out the picture. Non-specific by nature, these signs are routinely mistaken for respiratory conditions, and that misreading costs patients precious time.
Imaging opens the investigation: X-rays, CT scans, and PET scans map the lungs and surrounding organs, revealing what malignant cells may have touched. But imaging alone can't close the case. Biopsy does – confirming cancer cell presence and, critically, identifying tumor type. That distinction shapes everything that follows.
Surgery, chemo- and radiation therapy, targeted therapy, immunotherapy, dendritic cell vaccination, TACE – the toolkit is substantial. No two patients receive identical plans. Cancer type, stage, and overall health all feed into clinical decision-making, and availability of specific options varies considerably between facilities, systems, and countries. Personalization isn't a luxury here; it's the standard.
Stage determines everything. With stage 1 lung cancer treatment, survival rates reach approximately 70% – a compelling argument for early detection. Stage 2 drops to around 50%, Stage 3 to 25%, Stage 4 to roughly 10%. The numbers make one thing undeniable: catching it early saves lives.
Absolutely – and more often than assumed. Radon gas exposure, secondhand smoke (frequently undetected), environmental pollutants, genetic factors, occupational hazards – these aren't rare edge cases. They represent real, documented pathways to diagnosis for people who've never smoked a day in their lives.
Smoking tops the list – and even secondhand exposure carries meaningful risk. Air pollution from specific agents, genetic predisposition, prior chest radiation therapy: all elevate danger. None operates as a singular cause. Risk accumulates; it rarely arrives alone.
Start with smoking cessation and avoiding secondhand exposure wherever possible. Test your home for radon. Limit carcinogen exposure at work. Eat well, move regularly. These aren't dramatic interventions; they're consistent habits that compound into real protection over time.
In Germany, stage and complexity drive the numbers. Stage 1 typically falls between €15,000 and €25,000. Stage 2 lung cancer treatment ranges from €25,000 to €40,000, treatment of stage 3 lung cancer – from €40,000 to €70,000. Advanced Stage 4 therapies? Often €50,000 or more. Understanding costs upfront isn't optional – it's essential planning.
No universal answer exists. Surgery and radiation deliver strong results in early stages, where localized intervention is still possible. Advanced cases are a different challenge entirely – immunotherapy, dendritic cell therapy, and TACE have transformed outcomes for patients once considered difficult to treat. The best treatment is always the one built around the individual.
Side effects vary dramatically depending on what's used. Chemotherapy is systemic by nature – fatigue, nausea, hair loss, immune suppression all follow. Radiation targets a site but still causes fatigue and local skin irritation. Immunotherapy brings flu-like symptoms. TACE, by contrast, tends toward localized discomfort and mild systemic effects – a meaningful distinction for patients weighing their options.
The difference is delivery. TACE places chemotherapy directly into the tumor while cutting off its blood supply – targeted, precise, contained. Systemic chemotherapy travels the entire body to reach its target, affecting healthy tissue along the way. That difference in side effect profile isn't incidental; for many patients, it's the deciding factor.
CT and MRI carry the weight here – follow-up imaging tracks tumor size and flags any progression. Tumor marker analysis adds depth to what scans reveal. Monitoring with imaging and biomarkers isn't a formality; it's an active, ongoing component of the treatment strategy itself.
Partly. A family history raises risk, and specific genetic mutations create real predisposition. Still, environmental factors – smoking above all – carry far greater weight in most cases. Genetics loads the gun; lifestyle and environment largely pull the trigger.
Early-stage diagnosis opens the door to years of survival – sometimes many. Advanced stages compress that timeline, though innovative treatments keep pushing its edges outward. Treatment quality and timing of intervention are both modifiable factors – and they matter enormously.
Low-dose CT scanning makes it possible, particularly for high-risk individuals: long-term smokers, those with a strong family history. Early detection doesn't merely improve survival statistics – it expands the entire range of treatment options available. Screening is one of very few tools that genuinely intervenes before symptoms ever surface.
Persistent cough. Hoarseness. Fatigue, chest pain, unexplained weight loss – each one easy to attribute to something less serious. That's precisely the problem. These symptoms rarely trigger alarm in isolation, yet they're frequently the earliest signals the body sends. Delayed diagnosis traces back, again and again, to this kind of reasonable misreading.
Speed separates them. SCLC grows fast, spreads aggressively, and responds well to chemotherapy and radiation – yet remains difficult to cure. NSCLC is slower-moving, more common, accounting for roughly 85% of cases. Treatment strategies differ significantly between the two. Correct classification isn't optional; it's the foundation everything else is built on.
Recurrence doesn't close the door. Second-line chemotherapy, radiation, immunotherapy, targeted therapy – all remain available. Experimental approaches through trials may open paths not accessible elsewhere. The right direction depends on prior treatment history, how the cancer has evolved, and the patient's current health.
For advanced lung cancer, the 2-year survival rate is about 25% with standard treatment. However, it rises to around 60% with innovative methods (e.g., dendritic cell therapy, TACE, and other interventional procedures).
Standard lung cancer treatments often involve several chemotherapy or radiotherapy cycles over a few months. On the other hand, innovative therapies (e.g., TACE or immunotherapy) typically require up to four sessions.
Conventional lung cancer therapies can cause nausea, fatigue, hair loss, and immune suppression. In turn, modern targeted and interventional treatments are usually associated with mild, localized discomfort and fewer systemic effects.
The response rate for standard lung cancer treatment remains below 10%. In contrast, innovative treatments (e.g., dendritic cell therapy and TACE) achieve response rates of 45-65%.
No single institution holds an undisputed title – but certain names rise consistently to the top. University Hospital RWTH Aachen in Germany, Mayo Clinic, and Memorial Sloan Kettering in the US benchmark highest globally across outcomes, technology, and specialist depth. Reputation matters; so does matching a hospital's specific strengths to your diagnosis.
Multidisciplinary tumor boards – that's where complex decisions get made well. Combine that with high surgical volumes, advanced diagnostics, and demonstrated experience with your cancer type. Check accreditations, published survival rates, and pricing transparency. Cost deserves a seat at the table; it just shouldn't be the only one.
Memorial Sloan Kettering consistently exceeds national benchmarks across the US. In Europe, University Hospital Jena and ViDia Karlsruhe stand out – particularly for minimally invasive approaches. Statistics tell part of the story; surgical volume and genuine specialization tell the rest about the best lung cancer treatment in the world.
Board-certified thoracic oncologists. Regular tumor boards that convene across disciplines. High surgical volumes and radiation technology that includes proton therapy. Molecular testing capabilities that make personalized treatment genuinely possible – not just theoretical. The best centers build strategy around each patient, with outcomes and costs both addressed transparently.
Germany leads. The German Cancer Society certifies Lung Cancer Centers against strict quality criteria – University Hospital RWTH Aachen, University Hospital Jena, and ViDia Karlsruhe among them. Clinical excellence defines these centers; so does pricing transparency, which makes planning international treatment meaningfully less daunting.
Leading centers don't wait for innovations to become standard – they drive adoption. Dendritic cell therapy, targeted molecular therapies, robotic surgery, proton therapy: available now at premier institutions, not years from now. For complex or recurrent cases, access to emerging treatments can be the decisive variable.
Personalization defines the approach. Multidisciplinary tumor boards sequence and adjust combinations of immunotherapy, targeted therapy, and chemotherapy based on individual response. Symptom management runs alongside active treatment – not after it. Extending life matters; so does the quality of that life, at every step.
The list is extensive – and it matters. Low-dose CT screening, PET-CT fusion imaging, navigational bronchoscopy, VATS, da Vinci robotic systems, stereotactic body radiation therapy, proton therapy, molecular diagnostic platforms. Premier facilities don't deploy one or two of these – they integrate the full spectrum into a unified clinical ecosystem.
Germany has earned particular distinction. Specialized centers combine dendritic cell therapy with minimally invasive interventions, constructing treatment strategies calibrated to specific tumor types and stages. Complex cases – those that exhaust standard options elsewhere – often find pathways in German centers simply unavailable in other systems.
Choose treatment abroad and you will be sure to get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. DOI: 10.3322/caac.21660. [DOI]
[2] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. DOI: 10.1016/j.jtho.2015.09.009. [DOI]
[3] Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy – revisited. Nat Rev Drug Discov. 2011;10(8):591–600. DOI: 10.1038/nrd3500. [DOI]
[4] Lin M, Eiken P, Blackmon S. Image guided thermal ablation in lung cancer treatment. J Thorac Dis. 2020;12(11):7039–47. DOI: 10.21037/jtd-2019-cptn-08. [DOI]
[5] Pusceddu C, Sotgia B, Fele RM, Melis L. CT-guided thin needles percutaneous cryoablation (PCA) in patients with primary and secondary lung tumors: a preliminary experience. Eur J Radiol. 2013;82(5):e246–53. DOI: 10.1016/j.ejrad.2012.12.010. [DOI]
[6] Sersa G, Miklavcic D, Cemazar M, et al. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol. 2008;34(2):232–40. DOI: 10.1016/j.ejso.2007.05.016. [DOI]
[7] Kovács A, Bischoff P, Haddad H, et al. Long-term comparative study on the local tumour control of different ablation technologies in primary and secondary liver malignancies. J Pers Med. 2022;12(3):430. doi:10.3390/jpm12030430. [DOI]
[8] Shu-Qiang Jin, Huan-Yu Zhao, Bin Bai, Chun-Hui Ma, Hai-Li Cao. Transcatheter arterial chemoembolization improves clinical efficacy and life quality of patients with lung cancer and reduces adverse reactions. Am J Transl Res. 2021 Sep 15;13(9):10396–10403. [PMC free article]
[9] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. DOI: 10.1056/NEJMoa011954. [DOI]
[10] Huang Y, Ding J, Chen X, et al. Annual progress of clinical research on targeted therapy for non-small cell lung cancer in 2022. Cancer Innov. 2023;2(1):45–65. DOI: 10.1002/cai2.56. [DOI]
Read:
Treatment of stage 4 lung cancer in Germany
Article menu:
- Standard Lung Cancer Treatment Protocols
- Lung Cancer Therapy: Innovations
- Comparative Analysis of Lung Cancer Treatment Methods
- Lung Cancer Success Stories and Patient Testimonials
- Best Treatment Center for Lung Cancer
- Cost of Lung Cancer Treatment
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently Asked Questions of Our Patients About Lung Cancer Treatment
Don't know where to start?
Contact Booking Health
